Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Mus musculus | B cell leukemia/lymphoma 2 related protein A1a | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | Bcl 2 ous antagonist:killer | 0.01 | 0.2837 | 1 |
Mycobacterium ulcerans | esterase/lipase LipP | 0.0039 | 0 | 0.5 |
Trichomonas vaginalis | penicillin-binding protein, putative | 0.0039 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.01 | 0.2837 | 1 |
Trichomonas vaginalis | penicillin-binding protein, putative | 0.0039 | 0 | 0.5 |
Schistosoma mansoni | lipoxygenase | 0.006 | 0.0982 | 0.3461 |
Echinococcus granulosus | arachidonate 5 lipoxygenase | 0.006 | 0.0982 | 0.3461 |
Onchocerca volvulus | 0.0039 | 0 | 0.5 | |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0054 | 0.0708 | 0.0708 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0054 | 0.0708 | 0.0708 |
Mycobacterium leprae | conserved hypothetical protein | 0.0039 | 0 | 0.5 |
Echinococcus multilocularis | arachidonate 5 lipoxygenase | 0.006 | 0.0982 | 0.3461 |
Trichomonas vaginalis | D-aminoacylase, putative | 0.0039 | 0 | 0.5 |
Echinococcus granulosus | EGFP:Bcl2 fusion protein | 0.01 | 0.2837 | 1 |
Toxoplasma gondii | ABC1 family protein | 0.0039 | 0 | 0.5 |
Mycobacterium ulcerans | lipase LipD | 0.0039 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.01 | 0.2837 | 0.2837 |
Mycobacterium ulcerans | beta-lactamase | 0.0039 | 0 | 0.5 |
Onchocerca volvulus | 0.0039 | 0 | 0.5 | |
Schistosoma mansoni | bcl-2 homologous antagonist/killer (bak) | 0.01 | 0.2837 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0054 | 0.0708 | 0.0708 |
Echinococcus multilocularis | Bcl 2 ous antagonist:killer | 0.01 | 0.2837 | 1 |
Mycobacterium tuberculosis | Possible penicillin-binding protein | 0.0251 | 0.9919 | 1 |
Schistosoma mansoni | apoptosis regulator bax | 0.01 | 0.2837 | 1 |
Trichomonas vaginalis | D-aminoacylase, putative | 0.0039 | 0 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0039 | 0 | 0.5 |
Mycobacterium leprae | Probable lipase LipE | 0.0039 | 0 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0039 | 0 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0039 | 0 | 0.5 |
Echinococcus multilocularis | EGFP:Bcl2 fusion protein | 0.01 | 0.2837 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0039 | 0 | 0.5 |
Mycobacterium ulcerans | fusion of enoyl-CoA hydratase, EchA21 and lipase, LipE | 0.0039 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.01 | 0.2837 | 1 |
Trichomonas vaginalis | esterase, putative | 0.0039 | 0 | 0.5 |
Brugia malayi | Apoptosis regulator proteins, Bcl-2 family protein | 0.01 | 0.2837 | 0.2837 |
Loa Loa (eye worm) | hypothetical protein | 0.0054 | 0.0708 | 0.0708 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0039 | 0 | 0.5 |
Loa Loa (eye worm) | apoptosis regulator protein | 0.01 | 0.2837 | 0.2837 |
Loa Loa (eye worm) | follicle stimulating hormone receptor | 0.0253 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.01 | 0.2837 | 1 |
Trichomonas vaginalis | D-aminoacylase, putative | 0.0039 | 0 | 0.5 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0039 | 0 | 0.5 |
Onchocerca volvulus | 0.0039 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 11.5 um | PUBCHEM_BIOASSAY: TR-FRET secondary assay for HTS discovery of chemical inhibitors of anti-apoptotic protein Bfl-1. (Class of assay: confirmatory) [Related pubchem assays: 432 ] | ChEMBL. | No reference |
IC50 (binding) | = 12.3 um | PUBCHEM_BIOASSAY: In Vitro Bfl-1 Dose Response Fluorescence Polarization Assay for SAR Study. (Class of assay: confirmatory) [Related pubchem assays: 621, 432 ] | ChEMBL. | No reference |
IC50 (binding) | > 100 um | PUBCHEM_BIOASSAY: GAPDH Dose Response Colorimetric Assay. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.